CDK6, cyclin dependent kinase 6, 1021

N. diseases: 266; N. variants: 27
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Proliferation promotion roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis are existed and verified in human HCC, both tumor and serum circ-ZEB1.33 can serve as an indicator for the prognosis of HCC patients. 30123094 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE Furthermore, the inhibition effect of miR-214 on E2F2, cyclin-dependent kinase (CDK) 3 and CDK6 expression was assessed in HCC cell lines with miR-214 mimics/inhibitors to increase/decrease miR-214 expression. 26498144 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6. 27490780 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE Interestingly, analysis of p16 mutants indicated that the Cdk4 interaction domain is required for stimulation of HCC cell migration; however, knockdown of Cdk4 and Cdk6 showed that these proteins are dispensable for this phenomenon. 23894465 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE Further studies using the HCC Huh7 cell line transfected with XIAP siRNA or expression vector demonstrated that XIAP regulated the expression of CDK4, CDK6, and Cyclin D1 via NF-êB and PTEN pathways. 22429965 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including down-regulation of cyclin-dependent kinase 6 (CDK6) and integrin β1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGFβ1 involved in the control of proliferation, apoptotic cell death and HCC progression. 21499307 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 Biomarker disease BEFREE Among the various types of cell-cycle regulators, p16 and p27 are frequently inactivated in HCC and are considered to be potent tumor suppressors. p16, a G1-specific cell-cycle inhibitor that prevents the association of cyclindependent kinase (CDK) 4 and CDK6 with cyclin D1, is frequently inactivated in HCC via CpG methylation of its promoter region. p16 may be involved in the early steps of hepatocarcinogenesis, since p16 gene methylation has been detected in subsets of pre-neoplastic liver cirrhosis patients. p27, a negative regulator of the G1-S phase transition through inhibition of the kinase activities of Cdk2/cyclin A and Cdk2/cyclin E complexes, is now considered to be an adverse prognostic factor in HCC. 18350604 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.080 AlteredExpression disease BEFREE In p18INK4C- positive HCCs, p18INK4C dominantly interacted with Cdk4 rather than with Cdk6. pRb phosphorylated at serine(Ser) 780 was detected more frequently in p18INK4C - negative than in p18INK4C - positive HCCs. 15349907 2004